TY - JOUR
T1 - β-glucan
T2 - a potent adjuvant in immunotherapy for digestive tract tumors
AU - Wang, Meiyu
AU - Pan, Jinhua
AU - Xiang, Wu
AU - You, Zilong
AU - Zhang, Yue
AU - Wang, Junyu
AU - Zhang, Anren
N1 - The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Tongji University Affiliated Shanghai Fourth People’s Hospital Research Launch Special Fund (No.sykyqd0201), key clinical supportive specialist construction project of Hongkou District (No.HKLCFC202406), Basic Research Project of Discipline Boosting Program of the Fourth People’s Hospital Affiliated to Tongji University (NO.SY-XKZT-2023-1013) and the Tongji University Affiliated Shanghai Fourth People’s Hospital Talent Promotion Program Project (NO.SY-XKZT-2023-3005).
Publisher Copyright:
Copyright © 2024 Wang, Pan, Xiang, You, Zhang, Wang and Zhang.
PY - 2024/7/19
Y1 - 2024/7/19
N2 - The immunotherapy for gastrointestinal tumors, as a significant research direction in the field of oncology treatment in recent years, has garnered extensive attention due to its potential therapeutic efficacy and promising clinical application prospects. Recent advances in immunotherapy notwithstanding, challenges persist, such as side effects, the complexity of the tumor immune microenvironment, variable patient responses, and drug resistance. Consequently, there is a pressing need to explore novel adjunctive therapeutic modalities. β-glucan, an immunomodulatory agent, has exhibited promising anti-tumor efficacy in preclinical studies involving colorectal cancer, pancreatic cancer, and gastric cancer, while also mitigating the adverse reactions associated with chemotherapy and enhancing patients’ quality of life. However, further clinical and fundamental research is warranted to comprehensively evaluate its therapeutic potential and underlying biological mechanisms. In the future, β-glucan holds promise as an adjunctive treatment for gastrointestinal tumors, potentially bringing significant benefits to patients.
AB - The immunotherapy for gastrointestinal tumors, as a significant research direction in the field of oncology treatment in recent years, has garnered extensive attention due to its potential therapeutic efficacy and promising clinical application prospects. Recent advances in immunotherapy notwithstanding, challenges persist, such as side effects, the complexity of the tumor immune microenvironment, variable patient responses, and drug resistance. Consequently, there is a pressing need to explore novel adjunctive therapeutic modalities. β-glucan, an immunomodulatory agent, has exhibited promising anti-tumor efficacy in preclinical studies involving colorectal cancer, pancreatic cancer, and gastric cancer, while also mitigating the adverse reactions associated with chemotherapy and enhancing patients’ quality of life. However, further clinical and fundamental research is warranted to comprehensively evaluate its therapeutic potential and underlying biological mechanisms. In the future, β-glucan holds promise as an adjunctive treatment for gastrointestinal tumors, potentially bringing significant benefits to patients.
KW - beta glucan
KW - digestive tract tumors
KW - immunotherapy
KW - mechanism
KW - β-glucan receptor
UR - http://www.scopus.com/inward/record.url?scp=85200235805&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2024.1424261
DO - 10.3389/fimmu.2024.1424261
M3 - Journal article
C2 - 39100668
AN - SCOPUS:85200235805
SN - 1664-3224
VL - 15
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1424261
ER -